ArticleToxicon: X2023
Availability, accessibility and use of antivenom for snakebite envenomation in Africa with proposed strategies to overcome the limitations.
Article in Toxicon: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Hemoperfusion as Adjunctive Therapy in Severe Snake Envenomation Refractory to Antivenom: A Case Series.Clinical case reports · 2026Article
- Estimating the distributional impact of improving access to snake antivenom in urban and rural Lao People's Democratic Republic: An extended cost-effectiveness analysis.PLoS neglected tropical diseases · 2026Article
- Venom variation and the future of antivenom design: Integrating population venomics, evolutionary toxinology, and precision therapeutics.Toxicon: X · 2026Review
- Following theSocio-ecological practice research · 2026Article
- From scarcity to sustainability: Policy pathways for equitable snakebite antivenom access in Africa.PLOS global public health · 2026Review
- Cross-sectional survey of the incidence, mortality and socioeconomic burden of snakebite envenoming in India.Nature communications · 2025Article
- Health professionals' knowledge, attitudes, and practices in snakebite management: A study from high-burden areas in the Afar Region, Ethiopia.PLoS neglected tropical diseases · 2025Article
- Nationwide variation of snakebite incidence in Kenya: Community surveys as an integrated NTD approach.PLoS neglected tropical diseases · 2025Article
- The Effect of Two Preservation Techniques on the Yield, Percentage Solids, Electrophoretic Profile, Gelatinolytic Activity, and Brine Shrimp Lethality ofMolecules (Basel, Switzerland) · 2025Article
- Mapping Evidence on the Regulations Affecting the Accessibility, Availability, and Management of Snake Antivenom Globally: A Scoping Review.Tropical medicine and infectious disease · 2025Review
- The biology and toxinology of blunt-nosed vipers.npj biodiversity · 2025Review
- Clinical challenges, controversies, and regional strategies in snakebite care in India.The Lancet regional health. Southeast Asia · 2025Review
- Computational Strategies for Broad Spectrum Venom Phospholipase AJournal of chemical information and modeling · 2025Article
- Article
- [Evaluation of snakebite management cost at Saint Jean de Dieu Hospital in Tanguiéta, Benin].Medecine tropicale et sante internationale · 2024Article
- A polygeneric immunogen composed of 22 venoms from sub-Saharan African snakes to expand the neutralization scope of the EchiTAb-plus-ICP antivenom.Toxicon: X · 2024Article
- Snakebite envenoming in Africa remains widely neglected and demands multidisciplinary attention.Nature communications · 2024Article
- Article
- Compendium of medically important snakes, venom activity and clinical presentations in Ghana.PLoS neglected tropical diseases · 2023Article
- Special issue editorial: Resource mapping for the management of snakebite envenomation.Toxicon: X · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Africa remains one of the regions with the highest incident and burden of snakebite. The goal of the World Health Organization to halve the global burden of snakebite by 2030 can only be achieved if sub-optimal access to antivenoms in the most affected regions is addressed. We identified upstream, midstream, and downstream factors along the antivenom value chain that prevent access to antivenoms in the African region. We identified windows of opportunities that could be utilized to ensure availability, accessibility, and affordability for snakebite endemic populations in Africa. These include implementation of multicomponent strategies such as intensified advocacy, community engagement, healthcare worker trainings, and leveraging the institutional and governance structure provided by African governments to address the challenges identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.